Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07 Noviembre 2024 - 6:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced that it will release its financial results for the
third quarter 2024 after the market closes on Thursday, November
14, 2024. Management will host a webcast/teleconference the same
day at 4:30 p.m. Eastern Time to discuss the results and provide a
corporate update.
Webcast and Conference Call InformationTo
participate in the teleconference, domestic callers should dial
1-800-717-1738 and international callers should dial
1-646-307-1865. A live webcast presentation can also be accessed
using this weblink:
https://viavid.webcasts.com/starthere.jsp?ei=1688854&tp_key=0b14db1255.
A replay of the webcast will be available on the Celcuity website
following the live event.
About CelcuityCelcuity is a clinical-stage
biotechnology company focused on development of targeted therapies
for treatment of multiple solid tumor indications. The company's
lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and
mTOR inhibitor. Its mechanism of action and pharmacokinetic
properties are highly differentiated from other currently approved
and investigational therapies that target PI3K or mTOR alone or
together. A Phase 3 clinical trial, VIKTORIA-1, evaluating
gedatolisib in combination with fulvestrant with or without
palbociclib in patients with HR+/HER2- advanced breast cancer is
currently enrolling patients. More detailed information about the
VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2
clinical trial, CELC-G-201, evaluating gedatolisib in combination
with darolutamide in patients with metastatic castration resistant
prostate cancer, is enrolling patients. A Phase 3 clinical trial,
VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and
fulvestrant as first-line treatment for patients with HR+/HER2-
advanced breast cancer is expected to begin enrolling patients in
the second quarter of 2025. Celcuity is headquartered in
Minneapolis. Further information about Celcuity can be found at
www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:Celcuity Inc.Brian Sullivan,
bsullivan@celcuity.comVicky Hahne, vhahne@celcuity.com(763)
392-0123
ICR WestwickeMaria Yonkoski, maria.yonkoski@westwicke.com(203)
682-7167
Celcuity (NASDAQ:CELC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Celcuity (NASDAQ:CELC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024